The stock has broken out and retested, therefore may undergo a reversal rally. Trade is supported by brokerage calls and Supports Nearby.
Risk Reward Ratio - 2.5:1
SL is placed below support zone & the lower trendline. The target is placed near resistance.
BiondVax has signed definitive agreements with the Max Planck Society and the University Medical Center Göttingen to enter into a strategic collaboration for the development and commercialization of innovative COVID-19 nanosized antibodies (NanoAbs).
NanoAbs exhibited in-vitro neutralization of all COVID-19 variants of concern including Delta, and based on...
Based on historical movement, the trough could occur anywhere in the larger red box. The final targets are in the green boxes. The pending top should occur within the larger green box as has been the historical case. Half of all movement has ended in the smaller green box. In this instance, the signal indicated BUY on September 17, 2021 with a closing price of...
Glaxosmithkline ($GSK) testing the golden resistance level 1431.5 standing outside of the upper daily Bollinger Band. This level previously reversed Glaxosmithkline down in December of 2020 and in January of this year. Selected Alpha ranks the reversal factor of this resistance level 25 points – making it the strongest golden tracked by the system at the moment....
Amature trader here. There is a strong pattern on GSK which is now in wave IV of an ending diagonal. Price should go to 1170 but buy around 1200 to show confirmation of a new uptrend.
See here:
This is a weekly chart but over the next two years it may go up 660pts to 1900, could be worth a look
this is not investment advice :), I've lost more than I've won, but...
I previously posted a longterm stock position that I added to my portfolio. This was GSK (GlaxoSmithKline) which is trading at the lower levels of its range and has good growth potential but also a sturdy dividend yield of more than 5% each year.
This stock has seen some strong bullish momentum this week and has broken out of a consolidation structure. The...
GSK is trading around the multi year lows having bounced off of the long term support zone at 1300. I think this is a relative bargain at these levels with GSK being one of the Big Pharma Companies that is still trading way below the starting price for the year.
Pfizer, Johnson & Johnson and Roche are all either positive or around net zero YTD. Novartis is...
see full chart at www.tradingview.com
Gild
Entry $62 area
Target 1 $67
Target 2 $71
stoploss $59
Why this play?
Trump used Gild's drug as part of his treatment, if he pulls thru with a full recovery. they will probably start pumping the news about this company and it'll finally have enough momentum to move back to the upside.
What is Gild?
Gilead Sciences,...
see full chart at www.tradingview.com
GSK
Entry $39.70
Target 1 $42.45
Target 2 $45.50
Target 3 $48
stoploss 38.70
Why this play?
There are 4 general approaches to the Covid vaccine.
1.A "killed" coronavirus that will get recognized as foreign matter in the blood. (Sinovac/Dynavax)
2.Coronavirus proteins themselves, produced industrially in outside cell...
A good time to review the previous floor at 60.xx that we have been tracking for almost a year in $GILD. Here taking the latest misses in Q4 Earnings with a pinch of salt as the red carpet has been rolled out for Gild via China. Once again another buying opportunity given the latest progress around Phase III clinical trials:
On the Remdesivir (GS-5734) side,...
We keep seeing Clinical Stage Companies that are publicly traded, with new FDA Approvals, and the stocks are blasting off. Many of those are trading over $100 with no revenue, profits or earnings.
Here Merck is, sitting under $100, beating earnings, with record revenue and profit, and paying an almost 3.00% dividend....It is simply outrageous. Wall Street...
GSK is showing a macro uptrend.
Bearish divergence showing on the MACD and RSI.
I have marked the previous divergence also, which preceded a sharp fall.
We may be coming down to test the support line.
The 2007-2009 dip is shown (38%)
I like what they do , has been in my #DRIP for many years , but lousy experience for the longs on #trade , maybe option folks ..easy just buy puts and never calls ,LOL
